Your search matched 2 results
What Biogen’s Alzheimer’s Drug Approval Means for Life Sciences Companies | Blog
In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.
A New Drug Price Deal Signals Significant Policy Shift | Blog
This month policies aimed at lowering drug prices are back on the table.
Already have a RSS feed reader?
